Previous studies have reported that actionable mutations, such as EGFR mutations or ALK/ROS1 fusions, are present in approximately 5-20% of LCNEC cases, though prevalence varies depending on cohort composition and molecular testing methods [22]. Here, ALK is linked to large cell neuroendocrine carcinoma.